Greffex Reports 100% Survival in H5N1 Avian Infuenza Pre-Clinical Trials

January 29, 2021

Greffex presented unofficial pre-clinical trial data this week on its H5N1 vaccine candidate that it’s been working to develop under an NIH contract.

Early results are encouraging.  100% of the mice that received the Greffex H5N1 vaccine survived after being challenged with a lethal dose of H5N1.  Conversely, 100% of the mice that were not vaccinated died or were euthanized in less than a week for having lost excessive body weight.  Even the mice that received a single dose and a low dosage had 100% survival.

In addition to the survival tests the Greffex trials revealed strong T-cell and strong antibody responses, well in excess of the FDA requirements.  While more animal trials will be conducted in the near term, these early results are consistent with highly immunogenic results from previous tests sponsored by the NIH on Greffex’s H5N1 and MERS vaccines.